Remove 2014 Remove Drug Development Remove Magazine
article thumbnail

Why relationships are key in rare disease patient engagement

pharmaphorum

Real-world data is a vital part of rare disease drug development, but to get a true picture of patients’ unmet needs pharma should take a broader view of their lived experiences, says Xperiome’s Jeremy Edwards. He says he would like to see the industry engaging rare disease patients at every stage of drug development.

article thumbnail

Country focus: China & APAC’s growing medical needs bring opportunities and challenges

pharmaphorum

All these factors will support the growth of in-house R&D-driven pharmaceutical companies and bring more innovative drugs to Asian markets.”. George Underwood is the editor for pharmaphorum’s Deep Dive digital magazine. About the author. He can be contacted on LinkedIn.

article thumbnail

Key insights for a successful first-time product launch

pharmaphorum

Hale has noticed that pre-commercial companies tend to start launch planning a little too late in their drug development process. Ideally, companies should begin engaging KOLs around 24 months before the planned launch, during phase 2 of the drug’s development. About the author.